GlassScriptPhysician profile
Randolph P Cousins
NPI 1730260019
$3,196.99
in general payments reported to CMS, 2019-2025
31 companies · $617 in 2025
The $617 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $542 · 2022: $719 · 2023: $618 · 2024: $700 · 2025: $617.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,935.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,935.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $500.02 | 2021-2025 | |
| Myriad Genetic Laboratories, INC. | $485.10 | 2021-2025 | Prolaris, Myrisk |
| Endo Pharmaceuticals INC. | $281.17 | 2021-2024 | Xiaflex |
| Janssen Biotech, INC. | $268.21 | 2021-2025 | Erleada |
| Abbvie INC. | $200.74 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $159.82 | 2023-2025 | Orgovyx, Gemtesa |
| Astellas Pharma US INC | $144.95 | 2021-2025 | Xtandi, Veozah |
| Axonics, INC. | $122.89 | 2022-2024 | Axonics |
| Merck Sharp & Dohme LLC | $122.60 | 2022-2025 | Lynparza, Keytruda, Keytruda Qlex |
| Myovant Sciences INC. | $107.43 | 2021-2022 | |
| Tolmar, INC. | $104.66 | 2024-2025 | Jatenzo, Eligard |
| Endo USA, INC. | $87.28 | 2024-2025 | Xiaflex, Aveed |
| Clarus Therapeutics INC. | $83.61 | 2021 | |
| Teleflex LLC | $64.27 | 2023-2024 | Urolift |
| Bayer Healthcare Pharmaceuticals INC. | $63.03 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $55.30 | 2022-2023 | Yonsa |
| Olympus America INC. | $48.42 | 2024 | Itind System |
| Angiodynamics, INC. | $44.34 | 2022 | |
| Janssen Pharmaceuticals, INC | $28.39 | 2022 | |
| Urovant Sciences INC | $25.48 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.32 | 2021 | |
| Progenics Pharmaceuticals, INC. | $23.38 | 2023 | Pylarify |
| Coloplast Corp | $19.49 | 2022 | |
| Medtronic, INC. | $19.21 | 2022 | |
| Laborie Medical Technologies Corp. | $19.10 | 2024 | Endosheath Technology |
| Antares Pharma, INC. | $16.59 | 2021 | |
| Travere Therapeutics, INC. | $16.29 | 2021 | |
| Amgen INC. | $15.57 | 2022 | |
| Novartis Pharmaceuticals Corporation | $15.50 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $14.61 | 2022 | |
| 180 Medical, INC. | $14.22 | 2025 | Gentlecath Glide |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randolph Cousins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.